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Abstract 
Background: Alzheimer’s disease (AD) is a progressive, degenerative, and terminal disease without cure. There is an 
urgent need for a new strategy to treat AD. The aim of this study was to investigate the effects of intermittent hypoxic 
treatment (IHT) on cognitive functions in a mouse model of AD and unravel the mechanism of action of IHT.
Methods: Six-month-old APPswe/PS1dE9 (APP/PS1) male mice were exposed to hypoxic environment (14.3%  O2) 4 
h/day for 14 days or 28 days. Cognitive functions were measured by Morris water maze test after either 14 days or 42 
days of interval. Thereafter the distribution of amyloid plaque and microglial activation were determined by mouse 
brain immunohistochemistry, while the amyloid beta (Aβ) and inflammatory cytokines were measured by ELISA and 
Western Blot. Microarray was used for studying gene expressions in the hippocampus.
Results: IHT for 14 days or 28 days significantly improved the spatial memory ability of the 6-month-old APP/PS1 
mice. The memory improvement by 14 days IHT lasted to 14 days, but not to 42 days. The level of Aβ plaques and 
neurofilament accumulations was reduced markedly after the IHT exposure. IHT reduced the pro-inflammatory 
cytokines IL-1β, IL-6 levels, and β-secretase cleavage of APP processing which implies reduced Aβ production. Micro-
array analysis revealed a large number of genes in the hippocampus were significantly altered which are known to be 
metabolism-regulated genes.
Conclusions: This study provides evidence of the beneficial effect of IHT on the progression of AD by alleviating 
memory impairment, reducing Aβ accumulation and inflammation in the brain. IHT can be developed as a novel 
measure to relieve the progression of AD by targeting multiple pathways in the AD pathogenesis.
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Background
Intermittent hypoxia is broadly defined as repeated 
episodes of hypoxia interspersed with episodes of 
normoxia [1]. Since the 1940s, intermittent hypoxia 
treatment (IHT) has been commonly used for train-
ing pilots, mountaineers, and athletes to improve 
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performance by way of adaptation to reduce the oxy-
gen environment [2–4]. In recent years, more and 
more research evidenced that IHT can be beneficial 
for the treatment of a wide range of disea ses such as 
chronic heart and lung diseases, hypertension [5], 
iron-deficiency anemia [6], Parkinson’s disease, and 
ischemic coronary artery diseases [7–9]. As such, 
IHT has been applied for the treatment and preven-
tion of chronic bronchial diseases (e.g., asthma) as a 
non-invasive, auxiliary treatment, via initiating a cas-
cade of beneficial adaptive responses without adverse 
effects [10–14]. The cascade of IHT includes multi-
ple changes in metabolic pathways and inflammatory 
responses and promotes angiogenesis and neurogen-
esis, which are evident at various levels, from syste mic 
down to cellu lar [15–19]. However, the consequences 
of IHT on the pathological processes of Alzheimer’s 
disease (AD) are not defined.
AD is characterized by a progressive impairment 
of memory and other cognitive function [20, 21]. 
The incidence of AD is 15% among those 65 years 
and older and is close to 50% for those aged over 85 
years [22]. The pathological hallmarks are extracellu-
lar amyloid beta (Aβ) accumulation and intracellular 
neurofibrillary tangles (NFTs), which leads to synaptic 
degeneration, neuroinflammation, eventually neuronal 
death [23–28]. Despite the significant progress that 
has been made toward understanding the genetic and 
molecular biological basis of AD in recent years, psy-
chosocial and family nursing interventions, combined 
with acetylcholinesterase inhibitors and neuroprotec-
tive agents, are mainly used to alleviate AD symptoms, 
and there is no cure for AD yet [29]. It is critical to 
discover novel approaches, which could target multi-
ple key pathways in the pathogenesis of AD, to halt the 
progression of AD.
In this context, we first validated and confirmed the 
in  vivo effects of IHT on cognitive functions in APP-
swe/PS1-dE9 (APP/PS1) mice. APP/PS1 are double 
transgenic mice expressing a chimeric mouse/human 
amyloid precursor protein (Mo/HuAPP695swe) and a 
mutant human presenilin 1 (PS1-dE9), both directed 
to central nervous system neurons [30]. Both muta-
tions are associated with early-onset AD [31]. We 
found that IHT alleviated the cognitive deficits, and 
inhibited Aβ production thus reducing Aβ fibrils in 
6-month-old APP/PS1 mice, suggesting that IHT is 
an effective approach for inhibiting the onset of Aβ 
deposition. Furthermore, we identified the expression 
of a large number of genes in the mouse brain of the 
IHT group were altered, most of which were known to 




Male, 8-week-old APP/PS1 mice and C57/BL6J wild-
type mice were purchased from Beijing Huafukang Bio-
science Co. Ltd. (Beijing, China) and were housed at a 
constant temperature under a 12-h light-dark cycle with 
unlimited access to standard diet and water in the ani-
mal house of the Beijing Institute of Basic Medical Sci-
ences. All protocols involving the use of animals were 
conducted in accordance with the Institutional Animal 
Care and Use Committee of the Institute of Basic Medi-
cal Science. The mice were randomly assigned and all 
experiments were carried out double-blind.
IHT exposure
The 6-month-old mice were placed in a decompression 
chamber (model: DYC-DWI; Fenglei, China) and were 
exposed to a hypoxic environment (14.3%  O2, equal 
to 3000-m high altitude, at the velocity of 5 m/s in 10 
min) 4 h per day for 14 days or 28 days (n = 10–12 per 
group). The control groups were placed in the cham-
ber under normoxic conditions at the same time as the 
treatment groups and by the same experimenter. Rou-
tine blood test which measures the cells in the body 
through the blood was examined by an automated 
blood analyzer (SYSMEX, Kobe, Japan). Physiological 
indexes such as heart rate, breath rate, diastolic blood 
pressure (DBP), systolic blood pressure (SBP), mean 
blood pressure (MBP), and partial pressure of oxygen 
 (PO2) were measured by a noninvasive pulse oximeter 
for animals (MouseOx® Plus pulse oximeter, PA, USA).
Morris water maze test
The test was performed using a black circular pool of 
122 cm in diameter that was divided into 4 equal quad-
rants. A transparent circular platform (10  cm2) was 
submerged 1.5 cm beneath the water surface. The water 
temperature was adjusted to 19–22 °C. The water maze 
activity was recorded using a video camera and ana-
lyzed with a professional analysis system (ANY-maze 
system, Dublin, Ireland). The experimental procedure 
includes the platform trial and the probe trial. The plat-
form trial was performed for five consecutive days with 
a platform beneath the water, to measure the mice’s 
ability of learning and memory. Thereafter, the plat-
form was removed from the pool, and the probe trial 
was performed to measure the memory retention of the 
spatial position of the platform (n = 10–12 per group).
Immunohistochemistry
After the behavior test, the mice were deeply anesthe-
tized with sodium pentobarbital (50 mg/kg, i.p.) and 
Page 3 of 16Yue et al. Alzheimer’s Research & Therapy          (2021) 13:194  
then were perfused transcardially with 0.9% sodium 
solution, followed by 4% paraformaldehyde (Solar-
bio, Beijing, China). Their brains were immediately 
removed, then rear-fixed while dehydrating with 30% 
sucrose-formaldehyde solution at 4 °C until they sank to 
the bottoms of 5 ml centrifuge tubes. The brains were 
embedded by optimal cutting temperature compound 
(O.C.T. compound) (SAKURA, CA, USA) and then were 
cut into 40-μm-thick coronal sections (n = 6 per group).
Polink-2 puls® Polymer HRP detection system (PV9001/
PV9002, ZSGB-BIO, Beijing, China) was used to deter-
mine the distribution of amyloid plaques, neurofilament 
accumulations, and ionized calcium-binding adaptor mol-
ecule 1 (IBA1) immunoreactivity in mice brains. Briefly, 
the sections were pre-treated using heat mediated anti-
gen retrieval with sodium citrate buffer (pH6, epitope 
retrieval solution 1) for 20 mins, then the sections were 
incubated in 3% hydrogen peroxide deionized water for 10 
min to block endogenous peroxidase. After that, the sec-
tions were incubated respectively with primary antibody: 
mouse anti-amyloid precursor protein (APP)/Aβ (1:100, 
Cell Signaling Technology; USA), mouse anti-Neurofil-
ament-L (1:100, Cell Signaling Technology; USA), and 
rabbit anti-IBA1 (1:200, WAKO, Japan), 4 °C overnight. 
Horseradish enzyme-labeled anti-mouse IgG (or anti-
rabbit IgG) polymers were added to detect the primary 
antibodies and were visualized using an HRP detection 
system. Diaminobenzidine (DAB) (ZSGB-BIO, ZlI-9017, 
Beijing, China) was used as the chromogen. The sec-
tion was then rinsed with tap water, re-dyed, dehydrated, 
transparent, and sealed. Images have been captured by a 
pathological section scanner (NDP, Japan). The number of 
Aβ-positive plaques in the cortex and hippocampus for-
mation was calculated using Image Pro Plus 6.0 software. 
Briefly, 20 consecutive sections of each mouse cortex and 
hippocampus were imaged together and the areas and 
the total counts of Aβ-positive plaques in sections per six 
mouse brains of each group were determined using the 
software. The level of neurofilament accumulations and 
IBA1 immunoreactivity was measured by using the mean 
optical density of DAB staining.
The histofluorescence assay to detect the glycocalyx 
microvasculature was made with 10 μg/ml of Fluores-
cein Lycopersicon esculentum (Lectin) (Vectorlabs, 
Burlingame, USA). Brain slices were first washed 
three times with PBS and then incubated overnight 
with lectin (10 μg/ml) at 4 °C. The slices were washed 
three times with PBS and confocal microscope (Nikon, 
Tokyo, Japan) studies.
Mouse brain homogenate
In separate mouse groups, after sacrifice, the mouse brain 
was taken out from the skull and mixed with protein 
extraction buffer which was made up of Protein lysate 
(Applygen, Beijing, China) and a protease inhibitor cock-
tail (EASYpack, Roche, Basel, Switzerland). The brain was 
then homogenized by high-speed tissue grinder (Service-
bio, Beijing, China), and centrifuged with 12,000g at 4 °C 
for 10 min. The resulting supernatant was transferred to a 
new microcentrifuge tube and the protein concentrations 
were determined using a BCA protein assay kit following 
the manufacturer’s instructions.
Enzyme‑linked immunosorbent assay (ELISA)
The concentrations of Aβ1-40 and Aβ1-42 were determined 
by ELISA kits of Aβ1-40 (KHB344) and Aβ1-42 (KHB3481) 
(Invitrogen, California, USA). Tissues were treated with 
TBS and 5M guanidine/50 mM Tris HCL (pH 8.0) buffer 
before Aβ1-40 and Aβ1-42 ELISA measurement [32]. Changes 
in inflammatory cytokines (IL-1β, IL-6, TNFα) in the brain 
were detected by ELISA kits of IL-1β (SEA563MU), IL-6 
(SEA079MU), TNFα (SEA133MU) (Cloud-Clone, TX, 
USA). All the ELISA kits were used in accordance with the 
manufacturer’s instructions (n = 6 per group).
Western blotting
The hippocampus was dissected from mice brains and 
total protein was extracted. Equal amount of protein (20 
μg) was denatured for 10 min in loading buffer at 95 °C, 
separated by 10–15% sodium dodecyl sulfate polyacryla-
mide gel electrophoresis (SDS-PAGE), and transferred 
to PVDF membrane (Bio-Rad, CA, USA) for 2 h at 4 °C. 
Membranes were blocked in 5% skim milk powder in 
TBS-T (TBS plus 0.1% Tween-20) for 1 h at room tem-
perature. The membrane was then incubated with pri-
mary antibodies -- APP (1:1000), the components of the 
γ-secretase complex presenilin1 (PS1) (1:1000), beta-site 
APP-cleaving enzyme 1 (BACE1) (1:1000), Neurofilament-
L (1:1000), Aβ (1:1000) (Cell Signaling Technology, MA, 
USA), a disintegrin and metalloprotease 10 (ADAM10) 
(1:1000) (Abcam, Cambridgeshire, UK), low-density lipo-
protein receptor-related protein 1 (LRP1) (1:1000) (Cell 
Signaling Technology, MA, USA), Tau (1:1000) (Cell 
Signaling Technology, MA, USA), Tau-pS396 (1:1000) 
(Cell Signaling Technology, MA, USA), β-actin (1:10000) 
(Sigma-Aldrich, MO, USA) overnight at 4 °C. Followed 
by incubation with HRP-conjugated goat-anti-mouse or 
goat-anti-rabbit antibodies (1:10,000, Bio-Rad, CA, USA) 
for 1 h at room temperature, the membrane was detected 
using the ECL reagent (Bio-Rad, CA, USA). The band den-
sity was analyzed by Image J software (n = 6 per group).
Microarray
A mouse genome 70-mer oligonucleotide microar-
ray (n = 3 per group) was obtained from CapitalBio 
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Corporation (Beijing, China) [33, 34]. RNA extraction, 
amplification, labeling, and hybridization microarray 
imaging and data analysis were performed according 
to the manufacturer’s instructions (CapitalBio Corp., 
Beijing, China). Statistical method t test Benjamini-
Hochberg false discovery rate [BH-FDR] < 0.05, 2-fold 
change were used to screen out the significantly up- and 
downregulated genes after IHT. Gene Ontology (GO) 
Term annotation and Kyoto Encyclopedia of Genes and 
Genomes (KEGG) signaling pathway were used to ana-
lyze the function of altered genes.
Quantitative real‑time PCR
Total RNA was isolated from the three samples used in 
the microarray analysis, using TRIzol reagent according 
to the manufacturer’s instructions (Invitrogen, Carls-
bad, CA, USA). Reverse transcription was performed by 
a reverse transcription kit (Vazyme Biotech Company 
Limited, China). cDNA was amplified by real-time PCR 
using SYBR Green master mix (Vazyme Biotech Com-
pany Limited, China) as recommended by the manufac-
turer. Gene expression was calculated relative to β-actin. 
Oligonucleotide primer sequences were listed in Table 1.
Data analysis
All data are presented as means ± the standard error of 
the mean (SEM). Unpaired T test was used to compare 
data between the control and IHT groups respectively. 
The level of statistical significance was set at p < 0.05. All 
graphs were generated using GraphPad 8.0 software.
Results
IHT alleviates cognitive impairment in 6‑month‑old APP/
PS1 mice
IHT for 14 days or 28 days
Six-month-old APP/PS1 transgenic male mice were sub-
jected to intermittent hypoxia (14.4%  O2, altitudes of 
3000 m, 4 h/day) for 14 days or 28 days and then behav-
ioral tests were performed (Fig. 1a). Wild type 6-month-
old male C57/BL6J mice treated with the same IHT 
regime as the APP/PS1 showed no significant difference 
in the escape latency (p = 0.5243), the time to the first 
entry to the platform (p = 0.6746), the number of cross 
over the platform location (p = 0.9043), time spent (p = 
0.6831), the distance traveled (p = 0.2319), and the mean 
velocity (p = 0.2684) in the goal quadrant compared to 
the control group mice (Additional file 1: Fig. S1, a to f ). 
The results implied that IHT did not significantly affect 
the learning and spatial memory of the wild-type mice. 
IHT APP/PS1 mice showed a shorter latency to find the 
platform compared with APP/PS1 mice without IHT at 
day 5 (IHT 14 days: p = 0.0219; IHT 28 days: p = 0.0179) 
(Fig.  1b). APP/PS1 mice with IHT spent a significantly 
shorter time in first entry the platform compared with 
APP/PS1 mice without IHT (IHT 14 days: p = 0.0092; 
IHT 28 days: p = 0.0069) (Fig. 1c). APP/PS1 mice with 
IHT had significantly more crossing platform times in 
the probe trial at different time point compared with 
the mice without IHT (IHT 14 days: p = 0.0351; IHT 28 
days: p = 0.0139) (Fig. 1d). Furthermore, APP/PS1 mice 
with IHT spent significantly longer time (IHT 14 days: p 
= 0.0332; IHT 28 days: p = 0.0396) and longer distance 
(IHT 14 days: p = 0.0429; IHT 28 days: p = 0.0489) in 
goal quadrant compared with normoxic mice (Fig.  1e, 
f ). The results suggested that mice in the IHT group 
focused on looking for the platform in the goal quadrant.
The IHT did not significantly change the mean 
velocity (IHT 14 days: p = 0.2700; IHT 28 days: p = 
0.6588) (Fig. 1g), the heart rate, breath rate, DBP, SBP, 
MBP,  PO2, except the body weights which were sig-
nificantly reduced by IHT 14 days and 28 days (Addi-
tional file 1: Table S1). Routine blood test was examined 
after IHT 14 days, and we found IHT increased hem-
atocrit (HCT) (p = 0.0236) and hemoglobin (HGB) 
levels (p = 0.0116) (Additional file  1: Fig. S2, a to b), 
Table 1 QPCR primer sequences
APP amyloid precursor protein, Bace1 beta-site APP-cleaving enzyme 1, PS1 presenilin1, Cdk5 cyclin-dependent kinase 5, Cdk5r1 cyclin-dependent kinase 5 regulatory 
subunit 1, Csnk1α1 casein kinase 1 alpha1, Csnk1δ casein kinase 1 delta, Capn1 calpain1
Genes Forward Reverse
APP 5′-CCT TCT CGT TCC TGA CAA GTGC-3′ 5′-GGC AGC AAC ATG CCG TAG TCAT-3′
Bace1 5′-TGC TGC CAT CAC TGA ATC GGAC-3′ 5′-GGA ATG TGG GTC TGC TTC ACCA-3′
PS1 5′-GCA GTA TCC TCG CTG GTG AAGA-3′ 5′-CAG GCT ATG GTT GTG TTC CAGTC-3′
Cdk5 5′-GTA CTC CAC GTC CAT CGA CATG-3′ 5′-GCC ATT GTT CCT CAG TCG GTGT-3′
Cdk5r1 5′-TCA TCT CGG TGC TGC CTT GGAA-3′ 5′-TTG GCA CAG GAC AGC GAC TTCT-3′
Csnk1α1 5′-GAT GTC CAC TCC TGT TGA GGTG-3′ 5′-AAG GAT GCG GAA TAG CTG CCTC-3′
Csnk1δ 5′-CCA TCA ACA CGC ACC TTG GCAT-3′ 5′-CAT ACT TCT GCC TCT TGG TGGC-3′
Capn1 5′-CCT TGT TCA GCA AGT TGG CAGG-3′ 5′-TCC AGG CTG AAG CCA TTA GTGC-3′
β-actin 5′-ACT GTC GAG TCG CGT CCA -3′ 5′-GTC ATC CAT GGC GAA CTG GT-3′
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but did not significantly effect in the number of white 
blood cell (WBC) (p = 0.3911), red blood cell (RBC) (p 
= 0.4898), neutrophil (p = 0.5354), and platelet (p = 
0.5053) (Additional file 1: Fig. S2, c to f ). Both 14 days 
and 28 days of IHT significantly improved memory in 
6-month-old APP/PS1 mice; however, there was no dif-
ferences in behavior test (latency to first entry the plat-
form: p = 0.7531, crossing platform times: p = 0.5646, 
time in goal quadrant: p = 0.3677, distance in goal 
quadrant: p = 0.6731, the mean velocity: p = 0.2852) 
between the two groups. Hence, the 14 days IHT was 
used only in the subsequent experiments.
IHT for 14 days with intervals of 14 days or 42 days
To explore how long the memory improvement by IHT 
lasted, we next performed the behavior tests after 14 
days IHT following different interval times (14 days or 
42 days) in 6-month-old APP/PS1 mice (Fig. 2a). For the 
mice having 14 days IHT with 14 days of interval, the 
escape latency of the IHT group was significantly shorter 
compared to the control at day 5 (p = 0.0481) (Fig. 2b). 
Mice in IHT group spent a significantly shorter time in 
first entry the platform (p = 0.0086) (Fig. 2c), and longer 
time spent in the goal quadrant (p = 0.0187) (Fig.  2e). 
We observed no significant difference in the number of 
cross over the platform location (p = 0.0760) (Fig.  2d) 
and distance traveled (p = 0.0759) (Fig. 2f ) between the 
control and 14 days IHT with 14-day interval mice. For 
the mice treated with 14 days IHT with 42 days of inter-
val, we observed no significant difference in the escape 
latency (p = 0.0481) (Fig.  2b), in the time to first entry 
the platform (p = 0.5606) (Fig. 2c), number of cross over 
the platform location (p = 0.06497) (Fig 2d), and time 
spent (p = 0.2128) (Fig.  2e) and distance traveled (p = 
0.3603) (Fig.  2f ) in the goal quadrant compared to the 
control group mice. Similarly, IHT does not affect the 
Fig. 1 IHT for 14 days or 28 days alleviates memory impairment in APP/PS1 mice. a Schematic representation of the experimental design. 
6-month-old APP/PS1 mice were exposed to a hypoxic environment (14.3%  O2, 4 h/day) for 14 days or 28 days and then behavioral tests were 
performed. Mice with IHT had a shorter latency to find the platform (b), spent a significantly shorter time in first entry to the platform (c), as well as 
had significantly more crossing platform times in the probe trial at different time points (d), longer time (e) and longer distance (f) in goal quadrant 
compared to the control mice. The IHT did not significantly change the mean velocity (g). Tra, Opp, AdjL and AdjR are the number of platform 
crossings in the training, opposite, adjacent left, and adjacent right quadrants, respectively. Control mice (n = 11), mice with IHT 14 days (n = 11), 
mice with IHT 28 days (n = 10). *p<0.05; **p < 0.01; ns, not significant
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mean velocity (interval of 14 days: p = 0.3054; interval of 
42 days: p = 0.9411) (Fig.2g). This suggests that the mem-
ory improvement by 14 days IHT lasts to 14 days, but not 
to 42 days.
IHT in 6‑month‑old APP/PS1 mice reduces amyloid load 
and inflammatory response
Compared to the control mice, the APP/PS1 mice hav-
ing 14 days IHT significantly decreased the number of Aβ 
immunoreactive plaques in the hippocampus (Fig.  3b), 
but not in the cortex (Fig.  3a). Quantification showed 
that APP/PS1 mice were subjected to IHT for 14 days sig-
nificantly reduced plaque number by approximately 31% 
(p = 0.0012) in the hippocampus (Fig.  3g). While there 
was no significant change in plaque number (p = 0.8094) 
in the cortex (Fig. 3e). The beneficial effect of IHT on AD 
pathogenesis was further confirmed by counting the area 
of plaques in brain sections by image J analyses. The area 
of plaques in APP/PS1 mice were significantly decreased 
after 14 days IHT (cortex: p = 0.0104; hippocampus: p = 
0.0026) (Fig. 3f, h).
We next examined the microglial reactivity in mouse 
brains using IBA1 and the neurofilament accumulations. 
IHT (14 days) APP/PS1 mice significantly decreased the 
accumulates area formed by neurofilament accumula-
tions and IBA1 positive cells aggregation (Fig.  3c, d). 
Quantification showed that the accumulates area was 
reduced by nearly 20% (neurofilament accumulations: 
p = 0.0346; IBA1: p = 0.0122) in IHT group (Fig. 3i, j). 
There was no significant difference in lectin staining (p 
= 0.1993) (Additional file 1: Fig. S3). Lectins, which bind 
with high affinity to specific N-acetyl-D-glucosamine and 
poly-N-acetyl lactosamine sugar residues of endothe-
lial plasma membrane glycocalyx, are commonly used 
Fig. 2 The effect of IHT for 14 days with intervals of 14 days or 42 days in APP/PS1 mice. a Schematic representation of the experimental design. 
Six-month-old APP/PS1 mice with 14 days IHT followed by different interval times (14 days or 42 days) and then behavioral tests were performed. 
There was a significantly shorter escape latency at day 5 (b), shorter time in the first entry of the platform (c), and longer time spent in the goal 
quadrant (e) after 14 days IHT following 14 days of interval but not 42 days of interval compared to the control mice. However, there was no 
significant difference in the number of crossing over the platform location (d), distance in goal quadrant (f), and mean velocity (g) in both intervals 
of 14-day and 42-day groups. Control mice (n = 11), mice with IHT 14 days following interval of 14 days (n = 10) in mice with IHT 14 days following 
interval 42 days (n = 10); *p<0.05; **p < 0.01; ns, not significant
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markers for studying the endothelial cells [35]. In our 
study, there was no significant difference in vascular den-
sity in the APP/PS1 mouse brain between the IHT 14 
days and the control groups, this suggested that IHT may 
have no significant effect on vascular structure.
Then, we performed ELISA to analyze the levels of 
Aβ1-40 and Aβ1-42 in the hippocampus in mice with IHT 
14 days. The levels of Aβ1-40 and Aβ1-42 were reduced to 
75.96 ± 4.4% and 70.08± 7.52% respectively compared to 
controls (Aβ1-40: p = 0.0135; Aβ1-42: p = 0.0107) (Fig. 4a, 
b). These data indicate that IHT reduces the formation 
of plaques and Aβ production in the AD mice. We then 
examined changes in the pro-inflammatory cytokines 
IL-1β, IL-6, and TNF-α after exposure to IHT for 14 
days. The result indicated that IHT down-regulated 
the level of IL-6 (p = 0.0125) (Fig.  4c) and IL-1β (p = 
0.0110) (Fig. 4d) but did not affect the level of TNF-α (p 
= 0.0919) (Fig. 4e) in the brain tissue. These results dem-
onstrate that IHT reduces the inflammatory response. 
In our study, 14 days IHT reduces the plaque load and 
inflammatory in APP/PS1 mice, but we did not observe 
the effect on the plaque load and inflammatory with an 
interval of 14 days.
We next analyzed molecules related to the degradation 
of APP via Western blotting. The expression of APP (p = 
0.0775), PS1 (p = 0.0751), and α-Synuclein (p = 0.1166) 
(Fig.  5b, f, g) in brain tissue was not significant differ-
ence after IHT for 14 days, but we observed markedly 
increased ADAM10 (p = 0.0011) (Fig.  5c) and reduced 
BACE1(p = 0.0018) levels (Fig. 5d) in APP/PS1 mice with 
IHT 14 days, while the expression of Neurofilament-L (p 
= 0.0011) (Fig.  5e) and Aβ (p = 0.001) both down-reg-
ulated. We also measured Tau and LRP1 protein levels, 
and found Tau-pS396 was reduced after IHT (IHT 14 
days: p = 0.0093, IHT 28 days: p = 0.0205) (Additional 
file  1: Fig. S4) but there was no statistical difference of 
LRP1 level between two groups (p = 0.1458) (Additional 
file 1: Fig. S5). Taken together, these results demonstrate 
that IHT inhibits amyloidogenic APP processing.
Microarray analysis of gene expression in APP/PS1 mice 
after IHT
To determine the gene expression profile in the hip-
pocampus of APP/PS1 mouse after IHT, we performed 
microarray analysis representing 6,347 genes. Gener-
ally, there were 261 genes that were significantly up- and 
downregulated after IHT (t test BH FDR< 0.05, 2-fold 
change). GO term annotation and KEGG signaling path-
way were used to analyze the function of altered genes. 
The results showed that the most significant genes were 
mainly associated with energy derivation by oxidation of 
organic compounds, regulation of GTPase activity, and 
some metabolic processes at the biological process level 
(Fig. 6a). Among the top, the changed number of genes 
in GO annotations after IHT were “metabolic process,” 
“cellular process,” and “biological regulation” (Additional 
file 1: Table S2). In addition to annotation the function of 
genes, genes are involved in various pathways. The most 
significant pathways of enriched genes were ribosome, 
oxidative phosphorylation, and some neurodegenerative 
Fig. 3 IHT reduces neuropathological changes in APP/PS1 mice. a–d Representative immunohistochemical images stained with antibodies 
against Aβ (a, b), Neurofilament-L (c), and IBA1(d). The Aβ plaque numbers were significantly reduced in the hippocampus (g), but not in the cortex 
(e), while the area of Aβ plaques was significantly decreased in both cortex (f) and hippocampus (h) in mice with IHT 14 days compared to the 
control ones. The area of neurofilament accumulation (i) and IBA1-positive cells aggregation (j) were significantly reduced in mice with IHT 14 days 
compared to the control ones. n = 6; *p<0.05; **p < 0.01; ns, not significant
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diseases involved AD (Fig.  6b). Besides, the pathways 
with more enriched genes were Glycolysis/Gluconeo-
genesis and Citrate cycle (TCA cycle) (Additional file 1: 
Table S3). In general, the large numbers of genes with sig-
nificantly altered in IHT APP/PS1 mice are known to be 
metabolism-regulated genes.
Glycogen synthase kinase 3 beta (Gsk-3β) and cyclin-
dependent kinase 5 (Cdk5) are key molecules in the 
development of AD [36, 37]. GSK-3β, a major Tau kinase, 
has been found to be overactivated in the brains of AD 
patients [38, 39], it is responsible for the hyperphos-
phorylation of tau, which is an important component of 
NFTs, making it play a key role in the pathogenesis of 
AD [40]. GSK-3β is also involved in Aβ-induced toxicity 
through different mechanisms, it has been reported that 
Aβ blocks Wnt-mediated GSK-3β-inhibition leading to 
an increase in Aβ formation and tau hyperphosphoryla-
tion [41]. Further, GSK-3β is expressed in both microglia 
and astrocytes, as a modulator of inflammatory cytokine 
levels in the brain, promotes the production of cytokines 
[42]. A surprising result from the microarray study was 
that the expressions of several key genes involved in the 
regulation of AD pathology include the genes encoding 
microtubule-associated protein (Tau), the components 
of the γ-secretase complex PS1, Gsk-3β, protein phos-
phatase 2 (Ppp2ca), Cdk5, Cdk5r1, Capn1, Csnk1α1, and 
Csnk1δ decreased.
Quantitative PCR was performed to validate the altered 
expression levels of these genes using cDNA derived from 
total RNA of the brain tissue samples. There was a good 
agreement between the microarray and Q-PCR results 
(Fig. 6c–j). Relative quantitative analysis of gene expres-
sion was performed: APP (p = 0.6489) (Fig. 6c), Bace1 (p 
= 0.0013) (Fig. 6d), PS1 (p = 0.0490) (Fig. 6e), Cdk5 (p = 
0.0129) (Fig. 6f ), Cdk5r1 (p = 0.0043) (Fig. 6g), Csnk1α1 
(p = 0.0125) (Fig. 6h), Csnk1δ (p = 0.0066) (Fig. 6i), and 
Capn1 (p = 0.0016) (Fig. 6j). Consistently, the protective 
role of IHT on APP/PS1 mice probably acts on APP pro-
cessing and decreases Aβ production by inhibiting the 
GSK3β pathway.
Interestingly, most of the genes from our signature that 
are down-regulated after IHT such as Capn1, Csnk1δ, 
Fig. 4 IHT decreases the levels of Aβ1-40 (Aβ1-42) and the pro-inflammatory cytokines in the brain of APP/PS1 mice. Mice with IHT 14 days had 
reduced levels of Aβ1-40 (a) and Aβ1-42 (b), IL-6 (c), and IL-1β (d) in the brain compared to the control mice. However, the level of TNF-α was not 
changed by the IHT (e). n = 6; *p<0.05; ns, not significant
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Csnk1α1, Cdk5, and Cdk5r1, belong to p53 related path-
way. Increasing evidence has suggested p53 pathway 
plays a pivotal role in AD, implying that modulation of 
cell death pathways might be of therapeutic benefit in 
IHT and indeed in age-related neurological disorders.
Discussion
In this study, we provided evidence of the beneficial effect 
of IHT on the APP/PS1 mice as shown in the working 
model (Fig. 7). We demonstrated that 14 days IHT inhib-
ited Aβ production, reduced neuritic plaque formation, 
and alleviated the memory deficits in 6-month-old APP/
PS1 mice, suggesting that IHT could be used for the pre-
vention/treatment of AD. We further showed IHT alle-
viated AD pathogenesis by reducing β-secretase cleavage 
of APP processing thus decreasing Aβ production in the 
brain tissue. In addition, we found a large number of 
genes expression were significantly altered by IHT, most 
of which were known to be metabolism-regulated genes 
or be enriched in p53 pathway, implying that modulation 
of metabolism and cell death by IHT might be of thera-
peutic benefit in AD.
AD is a progressive neurodegenerative disease charac-
terized by cognitive decline and behavioral changes [43]. 
Formation of amyloid plaques and NFTs are two cen-
tral hallmarks in the AD. Amyloid plaques are the dense 
composites of Aβ which accumulates around the nerve 
cells, while NFTs are the twisted fibers containing hyper-
phosphorylated tau proteins present in certain residues 
of Aβ that build up inside the brain cells [44, 45]. The 
epitope defined by phosphorylation of S396 in tau pro-
tein is strongly implicated in AD-associated tau pathol-
ogy [46]. We found IHT could reduce Tau-pS396 protein 
levels and NFTs density in the APP/PS1 mice. High levels 
of fibrillary Aβ in the brain are associated with neuronal 
and synaptic loss and impairment of neuronal functions 
[47]. Aβ is a cleaved product of the APP via proteolysis by 
BACE1 and γ-secretase [48]. BACE1 is a prime drug tar-
get for slowing down Aβ production in early AD [49]. In 
AD, excessive accumulation of Aβ monomers results in 
their assembly into soluble, diffusible oligomers e.g. Aβ 
dimers which directly induce tau hyperphosphorylation 
and neurite degeneration [50]. In this study, we found 
IHT could reduce BACE1 while increasing α-secretase 
levels resulting in reduced Aβ plaque and deposition in 
6-month-old APP/PS1 mice. This is consistent with a 
number of studies that demonstrate cognitive improve-
ment following inhibition of Aβ generating enzymes in 
Fig. 5 IHT affects the amyloidogenic proteins APP processing. a Representative Western blots of APP, ADAM10, BACE1, Neurofilament-L, PS1, 
α-Syn, and Aβ. There was a significant increase of ADAM10 (c) and decrease of BACE1 (d) and Neurofilament-L (e) in mouse brain with IHT 14 days 
compared to the control mice. The expression of APP (b), α-Synuclein (f) and PS1 (g) in brain tissue was not significantly changed by the IHT. n = 6; 
**p < 0.01; ns, not significant
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mouse models of AD [51, 52]. LRP1 is highly expressed 
by neurons and has multiple functions in the regulation 
of cerebrovascular homeostasis and AD’ pathology. Many 
evidences have indicated that LRP1 mediates brain Aβ 
clearance and amyloid deposition [53–56], but in the pre-
sent study, IHT did not significantly affect LRP1 protein 
expression.
It has been demonstrated that there are increased 
amyloid brain levels in APP/PS1 mice since 3 months 
old while strong plaque deposition can be detected at 
6 months [57–59]. The previous studies from our and 
other groups have identified that Aβ aggregation was 
correlated with memory deficits in the APP/PS1 mice 
[60–62]. Consistent with this finding, we found 14 days 
of IHT significantly reduced Aβ protein expression and 
Aβ aggregation, improved the cognitive performance 
in APP/PS1 mice. The results indicated that IHT may 
serve as a protective role of Aβ-induced AD pathological 
processes.
The protein neurofilament-L is a key component of 
axons and the main byproduct of nerve cell degen-
eration. Research studies have shown neurofilament 
accumulations in many human neurological disorders 
including Parkinson’s disease, AD, Charcot-Marie-Tooth 
disease, and Amyotrophic Lateral Sclerosis [63]. It has 
been found in both cerebrospinal fluid and blood in AD 
patients [64, 65]. Neurofilament-L has been used as a 
biomarker and may monitor efficacy of disease-altering 
drugs in clinical trials with AD patients [65–69]. In our 
study, the expression of neurofilament-L protein was 
reduced by nearly 45% after IHT 14 days. IHT was found 
to promote hippocampal neurogenesis [15], to prevent 
overproduction of nitric oxide in the brain and neurode-
generation induced by Aβ toxicity [70], and to enhance 
brain-derived neurotrophic factor (BDNF) expression in 
9 months APP/PS1 mice [71].
Neuroinflammation, the inflammatory response of the 
central nervous system, can be caused as a result of Aβ 
plaques deposition and contributes to the progression 
of AD [72–74]. Although neuroinflammation has roles 
in protecting the brain, prolonged neuroinflammation 
has been known to increase Aβ burden and the plaque 
deposition creates a vicious cycle where the Aβ load is 
increased which further results in microglia activation 
Fig. 6 Microarray and qPCR analysis of differentially expressed genes in the hippocampus of APP/PS1 mice with IHT 14 days compared to the 
control ones. a Top enriched GO terms for the differentially expressed genes. b Top enriched KEGG pathways for the differentially expressed genes. 
The color represents the P-value. c–j were down-regulated genes by the IHT (c) APP, (d) Bace1, (e) PS1, (f) Cdk5, (g) Cdk5r1, (h) Csnk1α1, (i) Csnk1δ, 
and (j) Capn1. n = 3; *p <0.05; **p < 0.01; ns, not significant
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and subsequent neuroinflammation [73]. Increased 
expression of inflammatory mediators in postmortem 
brains of people with AD and epidemiological studies 
link the use of anti-inflammatory drugs with reduced risk 
for the disorder [75–80]. Nonsteroidal anti-inflamma-
tory drug treatment can reduce brain Aβ levels, amyloid 
plaque burden, and microglial activation in an animal 
model of AD [81]. CD11b-positive microglia and glial 
fibrillary acidic protein (GFAP) positive astrocytes were 
first detected at 3 months old APP/PS1 mice with a close 
association with amyloid plaques [82]. We found IHT (14 
days) significantly decreased the area of plaques formed 
by IBA1 positive cells aggregation in APP/PS1 mice. 
IBA1 is specifically expressed in macrophages/microglia 
antibody and the area of plaques formed by IBA1 posi-
tive cells aggregation shows the microglial reactivity [83]. 
The brains of APP/PS1 mice were under an active inflam-
matory stress, the amplitude of cytokine response TNF-
α, IL-6, and other inflammatory factors was dependent 
on Aβ levels [84]. IHT reduced the pro-inflammatory 
cytokines in mice: IL-1β (p < 0.05), IL-6 (p < 0.05), and 
TNF-α (p > 0.05) in their protein expressions in the brain. 
These data indicated that the effect of IHT on APP/PS1 
mice might be related to an inflammatory response.
Oxygen is vital to maintain the normal functions of 
almost all the organs [85]. The important roles of oxy-
gen are not only reflected in the development, but also 
in the pathological processes of many cerebral diseases 
[16]. Oxygen supply in brain tissue plays a key role in 
neurodegeneration during the aging process [86]. Previ-
ously studies reported that acclimatization to hypoxia 
when ascent to altitude is reflected by progressive 
increases in ventilation, adaptations in the cardiovas-
cular system that enhance oxygen delivery to tissues for 
better extraction of oxygen, and more efficient utiliza-
tion of oxygen for metabolic processes from the integra-
tive systems to the molecular and genomic level [19]. 
These adaptive responses raise the potential therapeutic 
Fig. 7 Working model of IHT alleviates memory impairment in 6-month-old APP/PS1 mice, reduces amyloid accumulation and inflammation in the 
brain. IHT for 14 days or 28 days, 14 days with interval of 14 days alleviates memory impairment in APP/PS1 mice. IHT reduced the pro-inflammatory 
cytokines IL-1β, IL-6 levels, and increased ADAM10 and decreased BACE1 of APP processing thus decreasing Aβ production
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possibility of IHT on these neurodegenerative diseases. 
There is also epidemiological evidence that resistance to 
altitude may impact the risk of death rates in AD, which 
each doubling of altitude was associated with a 2 per-
cent reduction in Alzheimer’s death rates [87]. A num-
ber of studies examined IHT’s safety and therapeutic 
efficacy in elderly patients with mild cognitive impair-
ment (MCI), a precursor symptom of AD. They suggest 
that adaptation to moderate IHT may enhance cerebral 
oxygenation, improve cognitive function, and decrease 
circulating biomarkers of AD [88, 89].
The beneficial effects of IHT to promote memory defi-
cits in the 6-month-old APP/PS1 mice are due in part 
to its ability to induce changes in gene transcription. 
We found that the expression of a wide variety of genes 
involved in IHT on AD pathogenesis is largely due to the 
regulation of Glycolysis/Gluconeogenesis, TCA cycle, 
APP processing, and cell death. The most significant 
pathways of enriched genes were ribosomes. Ribosomes 
are the cellular factories responsible for making proteins. 
It is the ribosome that reads the sequence of mRNA and 
translates it into the correct sequence of amino acids 
for each protein. Although no data are available regard-
ing the precise mechanism of IHT on neurodegenerative 
diseases, it provides new directions for neurology aimed 
at understanding mechanisms of IHT on aged-related 
diseases. Other mechanisms that could account for the 
effective roles of IHT need further investigation.
There are several different experimental models to 
study IHT in animals. The different protocol also has dif-
ferent effects on various diseases mainly depending on 
the intervals and the altitude of hypoxic exposures, the 
number of hypoxic episodes per day, and the number 
of exposure days. Goryacheva et  al. demonstrated IHT 
(4000 m for 14 days, 4 h per day) significantly alleviated 
the memory deficiency in rats with Aβ25-35 being injected 
into the basal macronuclei of the brain [70]. Suzuki dis-
covered short-duration of IHT (4 cycles of 12–13%  O2 for 
15 min and 20.9%  O2 for 10 min) for 28 days facilitated 
endurance exercise performance in mice [90].
On the contrary, Snyder et  al. found increased oxida-
tive stress and inflammation in a manner consistent with 
early stages of neurodegenerative disease in rats were 
exposed to 7 days chronic intermittent hypoxia for 8 h/
day [91]. Shiota et al. reported that chronic intermittent 
hypoxia/reoxygenation (5%  O2 and 21%  O2 every 10 min, 
8 h/day for 4 weeks) facilitates amyloid-β generation in 
AD model mice [92].
Recently, more and more studies have shown that some 
non-invasive stimuli can improve the cognitive behav-
ior and pathological changes of AD mouse models. The 
methods were different but showed similar positive 
results. A non-invasive light flicker (gamma entrainment 
using sensory stimulus or GENUS) furthermore, com-
bined auditory and visual GENUS, have been reported 
to improve spatial and recognition memory and reduce 
amyloid in AC and hippocampus of 5XFAD mice [93, 94]. 
Hyperbaric oxygen therapy (HBOT) attenuated neuroin-
flammatory processes and reduced amyloid burden, and 
tau phosphorylation in 3xTg mice, and ameliorated their 
behavioral deficits [32]. HBOT did the opposite of our 
study but showed very similar effects in terms of reduc-
ing beta amyloid pathology. The reason may be that IHT 
and HBOT both have wide-ranging effects on the brain 
to improve cognitive function through different mecha-
nisms [95].
Previous studies of our lab showed that the prolifera-
tion of neural stem cells in the hippocampal subventricu-
lar zone (SVZ) and dentate gyrus (DG) was significantly 
increased in adult rats with IHT for 2 weeks at 3000 m 
altitude [96]. In  vivo real-time oxygen probe detection 
revealed that oxygen content in the hippocampal DG 
region fluctuated significantly after IHT, and promote 
the growth of dendritic spines of hippocampal neurons 
[17]. IHT promotes neurogenesis leading to more new-
born neurons in the hippocampus in adult rats and stably 
enhanced the expression of BDNF to relieve the depres-
sant-like effects in animal models, suggesting that IHT is 
involved in BDNF signaling [15]. In contrast, chronic or 
severe hypoxia significantly alters neurotransmitter sys-
tems and produces progressive brain injury and subse-
quent impairment of neural function [97, 98]. This may 
be explained to the adverse effect of different episodic 
hypoxia to differentiate between physiological and patho-
logical responses in neurodegenerative diseases.
Limitations
This study has several limitations as follows: (i) it is well 
established that inflammation and hypoxia-induced path-
ways are different between sex, while we used only male 
AD mice in this study for reducing variants in the experi-
ments. It remains to be studied whether IHT has similar 
effects on female APPswe/PS1dE9 mice; (ii). considering 
the timeliness of IHT, we only adopted the water maze 
to test the spatial learning and memory ability of mice. 
The results will be more solid if other behavioral tests 
can be used without affecting the timeliness of IHT, for 
example, the Y-maze test and novel object location etc.; 
(iii). hypoxia is a double-edged sword, severe and persis-
tent hypoxia can cause damage to the body, while mild 
and temporary hypoxia can bring beneficial effects to the 
body. Our study represents a proof of concept; however, 
the duration of IHT can be further optimized; (iv). since 
AD is a chronic neurodegenerative disease, further stud-
ies are needed for validating these discoveries in the clini-
cal setting.
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Conclusion
In conclusion, this study demonstrates that IHT (14 
days and 28 days) improves spatial memory ability in 
6-month-old APP/PS1 mice. The improvement in spatial 
memory ability lasts to 14 days but not 42 days of inter-
val, indicating the beneficial effect of IHT is temporary. 
The spatial memory ability improvement by IHT is asso-
ciated with reduced formation of amyloid plaques and 
neurofibrillary tangles, as well as inhibition of neuroin-
flammation, and changes in gene expression in the hip-
pocampus. The genes that are down-regulated after IHT 
such as Capn1, Csnk1δ, Csnk1α1, Cdk5, and Cdk5r1, 
belong to p53 related pathway, suggesting the p53 path-
way plays a pivotal role in the process. Our study has fur-
ther clarified the therapeutic effect of IHT on APP/PS1 
mice, and explored the multi-target regulation mecha-
nism of its intervention effect. Although further research 
is needed to elucidate the underlying beneficial mecha-
nisms of IHT, we suggest that IHT presents a new means 
for treating AD.
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